Share and Follow
“Last year, we made Jardiance available to a select group of Australians suffering from a specific kidney condition. Starting Saturday, we anticipate that an additional 70,000 Australians with kidney disease will gain access to this transformative medication,” he announced on Tuesday.
Data from the 2021 Census indicates that kidney disease affects approximately 1% of the Australian population, with the condition being diagnosed in one in every twenty Australians aged 75 and older.
For those eligible patients who do not hold a concession card, the cost of a prescription is currently $31.60. This price is set to decrease to $25 starting next year.
Health Minister Mark Butler emphasizes that Jardiance, scientifically known as Empagliflozin, is significantly transformative for numerous Australians. Source: AAP / Mick Tsikas

Butler said kidney disease was a silent epidemic in Australia.